Table 1.

Targeted Monotherapy in Relapsed/Refractory Mantle Cell Lymphoma.

Drug	Study	Number of Patients	Median Lines of Therapy	ORR (CR) %	Median DOR (mos.)	Median PFS (mos.)	Most Common Grade ≥ 3 AEs	Reference
Bortezomib	Phase II	152	2	33 (8)	9.2	NR	Neuropathy (13%), Fatigue (12%), Thrombocytopenia (11%)	[28]
Lenalidomide	Phase II	26	3	31 (8)	22.2	3.9	Neutropenia (62%), Thrombocytopenia (42%), Anemia (15%)	[30]
Lenalidomide	Phase II	57	3	35 (12)	16.3	8.8	Neutropenia (46%), Thrombocytopenia (30%), Anemia (13%)	[31]
Lenalidomide	Phase II	134	3	28 (8)	16.6	4.0	Neutropenia (43%), Thrombocytopenia (28%), Anemia (11%)	[32]
Idelalisib	Phase I	40	4	40 (5)	2.7	3.7	Elevated AST/ALT (20%), Diarrhea (17.5%), Decreased Appetite (15%), Neutropenia (10%)	[33]
Parsaclisib	Phase II		1				Diarrhea (13.9%), Neutropenia (8.3%), Hypokalemia (3.7%), Colitis (3.7%)	[34]
BTKi pre-treated		53		30 (2)	NR	NR
BTKi-naïve		53		70 (16)	12.1	13.6
Ibrutinib	Phase II	111	3	67 (23)	17.5	13.0	Neutropenia (17%), Thrombocytopenia (13%), Anemia (11%), Hemorrhage (6%), Atrial Fibrillation (5%)	[22,35]
Ibrutinib	Phase III	139	2	72 (19)	NR	14.6	Neutropenia (13%), Thrombocytopenia (9%), Anemia (8%), Atrial Fibrillation (4%)	[36]
Ibrutinib	Meta-Analysis	370	2	70 (27)	21.8	12.5	Not reported	[37,38]
Acalabrutinib	Phase II	124	2	81 (40)	NR	NR	Neutropenia (10%), Anemia (9%), Pneumonia (5%)	[39]
Zanubrutinib	Phase II	86	2	84 (68)	19.5	22.1	Neutropenia (20%), Pneumonia/Lung Infection (9.3%)	[40]
Pirtobrutinib	Phase I/II		3				Infections (17.1%), Neutropenia (13.4%), Thrombocytopenia (6.7%), Hemorrhage (4%), Atrial Fibrillation/Flutter (1%)	[41]
BTKi pre-treated		90		58 (20)	21.6	7.4
BTKi-naïve		14		86 (36)	NR	NR
Venetoclax	Phase I	28	3	75 (21)	NR	14.0	Anemia (15%), Neutropenia (11%), Thrombocytopenia (9%)	[42]
Venetoclax	Retrospective	20	3	53 (18)	3.2	8.1	Pneumonia (15%), Thrombocytopenia (5%), Hemorrhage (5%), Sepsis (5%)	[43]